当前位置:
X-MOL 学术
›
Ann. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial
Annals of Oncology ( IF 50.5 ) Pub Date : 2017-06-16 , DOI: 10.1093/annonc/mdx300 P.M. Specenier , E. Remenar , J. Buter , D.L. Schrijvers , C. Bergamini , L.F. Licitra , A. Awada , P.M. Clement , C. Fortpied , J. Menis , J.B. Vermorken
Annals of Oncology ( IF 50.5 ) Pub Date : 2017-06-16 , DOI: 10.1093/annonc/mdx300 P.M. Specenier , E. Remenar , J. Buter , D.L. Schrijvers , C. Bergamini , L.F. Licitra , A. Awada , P.M. Clement , C. Fortpied , J. Menis , J.B. Vermorken
Our aim was to test the safety of cetuximab added to chemoradiation with either cisplatin or carboplatin after prior induction chemotherapy.
中文翻译:
TPF加西妥昔单抗诱导化疗,然后每周西妥昔单抗加每周顺铂或卡铂进行生物化学放疗:II期EORTC随机试验
我们的目的是在先行诱导化疗后,通过顺铂或卡铂对放化疗中加入西妥昔单抗的安全性进行测试。
更新日期:2017-09-18
中文翻译:
TPF加西妥昔单抗诱导化疗,然后每周西妥昔单抗加每周顺铂或卡铂进行生物化学放疗:II期EORTC随机试验
我们的目的是在先行诱导化疗后,通过顺铂或卡铂对放化疗中加入西妥昔单抗的安全性进行测试。